Description :GITR (glucocorticoid-induced TNF receptor family-regulated gene) is a 25 kD TNF receptorsuperfamily member (also known as AITR and TNFRSF18). GITR is expressed on activatedlymphocytes and is upregulated by T cell receptor engagement. The cytoplasmic domain ofGITR is homologous to CD40, 4-1BB and CD27 and has been shown to interact with TRAF 1-3, but not TRAF 5 or 6. GITR signaling has been shown to regulate T cell proliferation andTCR-mediated apoptosis, and to break immunological self-tolerance. GITR binds GITRL and isinvolved in the development of regulatory T cells and to regulate the activity of Th1 subsets.
Verified Reactivity :Human
Antibody Type :Monoclonal
Host Species :Mouse
Immunogen :Recombinant human GITR-Fc chimera
Formulation :Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation :The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™under optimal conditions.
Concentration :Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysis online tool.)
Storage & Handling :The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application :FC - Quality tested
Recommended Usage :Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in100 µl staining volume or 5 µl per 100 µl of whole blood.
Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm isrecommended for detection, although filter optimization may be required depending on otherfluorophores used. Be sure to verify that your cytometer configuration and software setup areappropriate for detecting this channel. Refer to your instrument manual or manufacturer forsupport. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license fromSirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use thepurchased product for research purposes only. This product may not be resold or incorporated inany manner into another product for resale. Any use for therapeutics or diagnostics is strictlyprohibited. This product is covered by U.S. Patent(s), pending patent applications and foreignequivalents.
1. van der Werf N, et al. 2011. J. Immunol. 187:1411.
2. Shimizu J, et al. 2002. Nat. Immunol. 3:135.
3. McHugh RS, et al. 2002. Immunity 16:311.
4. Kwon B, et al. 1999. J. Biol. Chem. 274:6056.